Compare Indofarma Tbk. (INAF) vs Jayamas Medica Industri Tbk. (OMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indofarma Tbk. vs Jayamas Medica Industri Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Jayamas Medica Industri Tbk. trades at Rp214 (market cap 5.79T, 9.53M 24h volume). The key difference: Jayamas Medica Industri Tbk. is far larger — about 14.8× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.
| INAF | OMED | |
|---|---|---|
Market Cap | 390.51B | 5.79T |
Volume | — | 9.53M |
Lot | — | 95.3K |
Turnover | — | 2.05B |
Average Price | — | 215.03 |
Value | — | 2.05B |
Indicative Equilibrium Price | — | 214 |
Indicative Equilibrium Volume | — | 1.69K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indofarma Tbk.
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Read more on INAF →About Jayamas Medica Industri Tbk.
PT Jayamas Medica Industri Tbk (the Company) was established based on Notarial deed No. 5 dated15 December 2000 of Devi Chrisnawati, S.H., Notary in Surabaya. The Company started its commercial operations since 2002.
Read more on OMED →
